Tandem Diabetes Care Inc 2025年季度报告

FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the Quarterly Period EndedJune 30, 2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission File Number001-36189 Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) (858)366-6900(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: TNDM Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes x No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growthcompany. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of August1, 2025, there were67,569,471shares of the registrant’s Common Stock outstanding. TABLE OF CONTENTS TANDEM DIABETES CARE, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except par value) TANDEM DIABETES CARE, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(Unaudited)(In thousands) TANDEM DIABETES CARE, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands) TANDEM DIABETES CARE, INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1.Organization and Basis of Presentation The Company Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advancedautomated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, theirloved ones and healthcare providers. Tandem Diabetes Care, Inc. is incorporated in the state of Delaware. Unless the context requiresotherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries. The Company manufactures, sells, and supports insulin pump products that are designed to address the evolving needs andpreferences of differentiated segments of the insulin-dependent diabetes market. The Company offers an insulin pump portfolio, whichincludes both the t:slim X2 and the Tandem Mobi. Both pumps feature Control-IQ+ technology, which is the Company’s advancedalgorithm for managing insulin delivery, using information received from integrated continuous glucose monitoring (CGM) sensors.New software for the insulin pumps may be updated remotely by the individual users as new advancements become available and arecompatible with other complementary digital health offerings, such as the Company’s mobile application and cloud-based diabetesmanagement applications. The Company’s durable insulin pump products generally have an expected lifespan of at leastfour years. Inaddition to insulin pumps, the Company sells single-use components that are used together with the pumps and are replaced every fewdays, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body. Basis of Presentation and Principles of Consolidation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance withaccounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuantto the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information anddisclosures required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments which are of anormal and recurring nature and considered necessary for a fair presentation of the financial information contained herein have beenincluded. Interim financial results are not necessarily indicative of results anticipated for the full year or any other period(s). Theseunaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidatedfinancial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year endedDecember31, 2024 (Annual Report), from which the condensed consolidated balance sheet presented as of December 31, 2024 hereinwas derived. The condensed consolidated